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Background: Recent studies have shown that Bacillus Calmette-
Guerin (BCG) vaccination is inversely related to asthma, a Th2
cellYassociated with allergic disease, which BCG in humans induces
Th1-cell immune responses and prevents airway remodeling.
Objective: To investigate whether thrice BCG vaccinations are
clinically effective and could induce laboratory improvement
compared with placebo on phase 1 (12 weeks) and single BCG
vaccination on phase 2 of the study, then ﬁnding out whether the
effect might last until 9 months after thrice vaccination and 9 months
after single vaccination on adult atopic extrinsic asthma.
Methods: According to the Global Initiative for Asthma criteria, 40
mild to moderate persistent atopic asthma patients were randomly
assigned in a double-blind fashion into groups that received intra-
dermal injection of 0.1 mL of BCG (n = 20) or 0.1 mL of placebo
(n = 20) on the ﬁrst day. On the ﬁrst phase, subjects on BCG
vaccinations were given intradermal injections 3 times on the deltoid
region every 4 weeks. On the second phase, at the 12th week, the
placebogroupwas given BCGvaccination once, and this group became
the single BCG group. The symptom score (SS) and drug score (DS),
lung function, eosinophil blood count (EBC), total serum immunoglo-
bulin E, interferon-F (IFN-F), interleukin 4, and transforming growth
factor-A1 (TGF-A1) were examined on the ﬁrst phase (before the
treatment and at the 12th week) and on the second phase (on the sixth
and ninth months after the third vaccination for thrice BCG group or
after single BCG for control group) to monitor the efﬁcacy.
Results: There were some improvements of asthma SS (P G 0.05)
and DS (P G 0.05), forced expiratory volume in 1 second (P G 0.05),
peak expiratory ﬂow rate (P G 0.05), EBC (P 9 0.05), IFN-F (P G
0.05), and TGF-A1 (P G 0.05) on thrice BCG group compared with
prevaccination and with placebo on the ﬁrst phase and second phase
of the study compared with single BCG (formerly placebo).
Conclusions: Based on the previous ﬁndings, we could conﬁrm that
thrice BCG vaccinations proved to be better than the placebo group
and single vaccination. The efﬁcacy of thrice BCG vaccinations on
asthmawas detected by the improvement of SS, DS, forced expiratory
volume in 1 second, peak expiratory ﬂow rate, EBC, IFN-F, and TGF-
A1 until 9 months from the last vaccination without any side effects.
Key Words: BCG, symptom/drug score, IFN-F, IL-4, TGF-A1,
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In Indonesia, the prevalence of asthma ranges from 3.8% to6.9%.1 In the past decades, treatment of asthma had empha-
sized long-term suppression of airway inﬂammation plus relief
of symptoms. Inhaled corticosteroids proved to be the most
effective agents available on asthma symptomatic control in
improving pulmonary function, but potential side effects might
occur when increasing the dosage, whereas corticosteroids do
not consistently abrogate airway inﬂammation.2 Conventional
allergen immunotherapy can be effective in many, but not all,
patients. Furthermore, an allergist is needed for possible
anaphylaxis reaction.3 Therefore, because of limited treatment
of asthma, which is relatively high cost, we need a new
modality that is more effective, safer, and cheaper.4
Bacillus Calmette-Guerin (BCG) is a vaccine used against
tuberculosis and as an immunomodulator that primes Th1
lymphocytes to produce cytokines that antagonize atopy in
animal models and in human clinical trials.5Y9 Considering
atopy as the main risk factor for asthma, we hypothesized that
vaccination inducing Th1 responses can be protective against
asthma because the Th1 and Th2 cells were reciprocally
regulated.10,11 These hypotheses are based on observations
that there was a negative signiﬁcant correlation between
tuberculosis rates and asthma prevalence in children, reduced
rating of current asthma symptoms of Japanese school
children,12 and that in murine models of allergen-induced
airway eosinophilia, intranasal BCG infection 4 weeks before
allergen airway challenges resulted in a 90% to 95% reduction
in eosinophilia within the lungs compared with uninfected
control mice.10 There were also a number of reports in Chinese
medical literature from the past 30 years that repeated
administration of BCG is effective in the management of
asthma.13,14 Also from the regions where tuberculosis is
prevalent,4,15Y19 they reported on an association between BCG
vaccination and lower rates of atopic disorders. A recent study
of Choi and Koh20 suggested that repeated BCG vaccinations
might be more effective in atopic asthma than once. There is
no conclusive evidence of the efﬁcacy of BCG against allergy,
although the association between BCG and asthma remains a
matter of debate.4,20Y23
This article describes an original, randomized, con-
trolled, double-blind, pretest and posttest clinical trial to
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investigate the efﬁcacy of BCG vaccinations on adult atopic
asthma patients during a 12-month cohort study.
METHODS
Patients
Adult atopic asthma patients were recruited from the
Allergy-Immunology outpatient clinic, Prof. RD Kandou
Hospital, Sam Ratulangi University, Manado, Indonesia. All
patients had asthma for more than 1 year and fulﬁlled the
criteria for mild and moderate asthma set down by the Global
Initiative for Asthma 2002.24 All patients were reluctant to take
fenoterol and budesonide inhaler from the ﬁrst until the second
vaccination, and discontinued budesonide inhaler since the
ﬁrst day of the third vaccination. The subjects were clinically
stable for at least 4 weeks before entering this study. Candidates
were excluded from the study based on these criteria: chronic
obstructive pulmonary disease, acute infectious diseases,
smoking at least for 1 year before, malignancies, cell-mediated
immune deﬁciency, human immunodeﬁciency virus, severe
dermatitis on deltoid, severe nutritional deﬁciency, rheumatoid
arthritis, osteoarthritis, systemic lupus erythematosus, multiple
sclerosis, previous speciﬁc immunotherapy, pregnancy, or
lactation. This study was approved by the ethical research
committee of the School of Medicine, Sam Ratulangi
University. All patients were informed about the experimental
procedures and provided written informed consent.
Study Design
This study was designed as a prospective, randomized,
placebo-controlled, pretest-posttest, and double-blind clinical
trial. The ﬁrst phase was done from March to August
2004, and the second phase was done from January to April
2005. On the ﬁrst day before the trial, we carried out
spirometry and peak expiratory ﬂow rate (PEFR) determina-
tion to diagnose the severity of asthma, and also collection of
blood samples for determination of eosinophil blood count
(EBC), total serum immunoglobulin E (IgE), interferon-F
(IFN-F), interleukin 4 (IL-4), and transforming growth factor-
A1 (TGF-A1) levels. After the run-in period, the patients were
randomly divided into 2 groups (BCG or placebo) and
intradermally given BCG or placebo (BCG solvent) vaccina-
tion 3 times, each at 4-week intervals. Inevitable development
of erythema at the vaccination site in the BCG group posed a
problem for the maintenance of the double-blind trial. In
regard to this problem, the study coordinator adjusted the
asthma medication without examining the vaccination site,
and other investigators monitored adverse reactions. Further-
more, all patients were given information to believe that BCG
vaccination produced by Biopharma Pharmacy generally
produced minimal or no reaction; and none of the patients
TABLE 1. Baseline Characteristics of Prevaccinated Asthma





(n = 20) P
Sex (male/female) 10 (50%)/10 (50%) 8 (40%)/12 (60%) 0.990
Age, yrs (mean T SD) 34.95 T 11.55 34.90 T 12.32 0.675
Body mass index, kg/m2
(mean T SD)
23.35 T 3.16 22.97 T 2.70 0.689
Old healed TBC lesions 0 0 0.5
History of anti-TBC drugs 0 0 0.5
Previous BCG
vaccination scar
14 (70%) 15 (75%) 0.517
Asthma triggers, no. (%)
Dust mite 12 (60) 13 (65) 90.05
Cold air 10 (50) 8(40) 90.05
Pollutant 9 (45) 8 (40) 90.05
Drugs 4 (20) 4 (20) 90.05
Seafood 2 (10) 4 (20) 90.05
Pollen 1 (5) 0 90.05
Duration of asthma, yrs (no. [%])
1Y3 2 (10) 3 (15) 90.05
3Y5 4 (20) 5 (25) 90.05
5Y10 9 (45) 8 (40) 90.05
910 5 (25) 4 (20) 90.05
Asthma grading (GINA 2002)
Mild persistent 6 (30%) 6 (30%) 0.5
Moderate persistent 14 (70%) 14 (70%) 0.5
Hemoglobin, g/dL 14.76 T 1.53 14.42 T 1.68 0.508
Eosinophil in differential
count, %
9.85 T 6.70 9.80 T 6.52 0.190
Student t test for continuous variables; Fisher exact test for categorical variables.
FIGURE 1. Trial design.
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asked whether they had received BCG vaccination or placebo.
The objective and clinical measures were repeatedly done on
weekly visits until the end of 12th week and then on the sixth
month until the ninth month trial period; EBC and cytokine
levels were analyzed again on the 12th week for the ﬁrst phase,
and on the sixth and ninth months for the second phase.
Clinical asthma evaluation was derived on 4 symptoms
(daytime dyspnea, daytime wheezing, daytime coughing, and
nighttime of one of those signs) scoring from 0 to 3, which
means 0 for no attack, 1 for mild attack, 2 for moderate attack,
and 3 for severe attack. It was called mild attack if asthma did
not disturb daily activity, moderate attack if it slightly
disturbed daily activities and sleeping, and severe attack if it
badly disturbed daily activity and sleeping. Long-acting
corticosteroid inhaler (budesonide, 100 Kg per puff) and
short-acting A2-agonist inhaler (fenoterol hydrobromide,
100 Kg per puff) were used. Budesonide was given in 1 puff
in the morning for the treatment of mild persistent asthma,
whereas for moderate persistent asthma, 1 puff each in the
morning and in the evening. Budesonide inhalations were
given only until the third vaccination (8 weeks from the ﬁrst
vaccination) to minimize the effect of corticosteroid on
immunostimulation. Fenoterol inhalation was given as needed
and was used for evaluating drug score (DS) between both
groups. Zero for not used, 1 for 1 puff, 2 for 2 puffs, 3 for 3 or
more puffs per day. Measurements of PEFR with the mini-
Wright peak expiratory ﬂowmeter from Clement Clark
International Ltd, England, were done during the 4-week
run-in period, 4 weeks after the ﬁrst, second, and third
vaccination, and then every month until 9 months. Measure-
ments of forced expiratory volume in 1 second (FEV1) and
mid-maximal expiratory volume (MMEV) with spiroanalyzer
ST-250 Fukuda Sangyo were done prevaccination and every
week until 4 weeks after the third vaccination in the morning at
8:00 to 10:00 am only in the ﬁrst phase. The highest value
among the 3 evaluations was taken as the best one in the study.
Atopy diagnosis was based on total serum IgE greater than
120 IU/mL (reference range, G120 IU/mL for adults 13 years
or older). Measurement of IgE was done using an enzyme-
linked immunosorbent assay. Measurement of EBC was done
with manual techniques using eosin yellow 2%, acetone, and
Neubauer counting chamber. Serum IFN-F, IL-4, and TGF-A1
levels were measured using an enzyme-linked immunosorbent
assay (Quantikine K human IFN-F immunoassay, IL-4 HS
400, HS TGF-A1, R and D systems, Minneapolis, Minn); all
were measured on prevaccination, at 12 weeks, at the sixth
month, and at the ninth month after the third vaccination. The
BCG vaccine contained live attenuated Mycobacterium bovis
from Pasteur Paris Strain No.1173.P2, produced by PT
Biofarma Bandung, Indonesia. The solvent of BCG, saline
solution, was used for the placebo vaccination for the ﬁrst
phase. During the study, if there were acute asthma
exacerbations, the patients were allowed to have A2-agonist
oral/inhalation, aminophylline, with or without oral short-
acting corticosteroid. They were also suggested to come every
4 weeks and to avoid allergens in both groups. All local or
systemic symptoms including autoimmune responses were
noted during the study from 4 weeks, until 12 weeks, and 6
FIGURE 2. The SS and DS on BCG
vaccination.
FIGURE 3. The PEFR and TGF-A1
levels on BCG vaccination.
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and 9 months after the last vaccination. On the second phase,
the patients in the placebo group were each given a single
BCG vaccination. The trial design is shown in Figure 1.
Statistical Analysis
The primary end points showed weekly changes in signs
and symptoms and spirometry (PEFR, FEV1, and MMEV)
above the baseline values, measured at the end of the run-in
period. Secondary end points included changes in EBC,
IgE, and serum IFN-F, IL-4, and TGF-A1 levels. The baseline
values for each of the variables recorded in the diaries were
determined as the averages or sums of weekly values for 4
weeks of the run-in period for the ﬁrst phase and then every
week until 9 months. Categorical variables were compared by
using the Fisher exact test for intergroup differences. The
differences in continuous variables between the 2 groups were
analyzed using the unpaired Student t test for parametric data
and Mann-Whitney U test for nonparametric data. The dif-
ferences within the same group were analyzed by using the
paired Student t test for parametric data and the Wilcoxon
signed rank test for nonparametric data. A P G 0.05 value was
considered statistically signiﬁcant.
RESULTS
From 52 patients who participated in the run-in period,
40 patients completed the study; 12 patients withdrew be-
cause of missing clinical and data visiting. The patient demo-
graphics and baseline characteristics were similar for the 2
groups; there are no signiﬁcant differences in all parameters
(Table 1). None of BCG group and placebo group in the ﬁrst
phase reported severe soreness at the site of vaccination.
FIGURE 4. Blood eosinophil and total IgE levels on BCG vaccination.
TABLE 2. Median/Mean Values of Spirometry, Blood Eosinophil Count, TSIgE and Serum Cytokines, Prevaccination and
Postvaccination on Both Groups on First and Second Phases
Dependent Variables Prevaccination
Postvaccination
4 Wk 8 Wk 12 Wk 6 Mo 9 Mo
Thrice BCG Group
PEFR (L/min) 360.5 T 61.1 403.5 T 71.9*,† 409.5 T 63.9*,† 428.0 T 77.6*,† 398.3 T 101.0*,‡ 380 T 86.1§,‡
FEV1 (L) 2.02 T 7.6 2.33 T 0.7*
,†
MMEV (L/s) 2.52 T 1.3 3.12 T 1.3*,†
Eosinophil count (/KL) 608 T 493.1 516 T 522.1§,‡ 453.9 T 313.1§,‡ 410 T 299.0*,‡
TSIgE (IU/mL) 1366 T 1934.6 1395 T 1563.7§,‡ 1502.82 T 2184.0§,‡ 1440 T 2084.4§,‡
IFN-F (pg/mL) 3.55 T 2.2 4.22 T 3.8§,‡ 4.58 T 2.8*,† 4.67 T 0.5*,‡
IL-4 (pg/mL) 0.04 T 0.039 0.08 T 0.05*,‡ 0.09 T 0.03*,† 0.1 T 0.04*,†
TGF-A1 (pg/mL) 54,396 T 6908 50,720 T 7111.4*,‡ 38,066 T 9279||,‡ 48,271 T 9634||,‡
Placebo Group Single BCG Group
PEFR (L/min) 360 T 53.3 343 T 67.4§,† 325 T 63.8*,† 315.50 T 72.9*,† 371 T 73.98§,‡ 346 T 95.8§,‡
FEV1 (L) 2.04 T 0.65 1.64 T 0.5*
,†
MMEV (L/s) 2.51 T 1.2 2.01 T 1.95*,†
Eosinophil count (/KL) 649 T 580.7 393 T 358.4*,‡ 569 T 553.7§,‡ 593 T 582§,‡
Total IgE (IU/mL) 887 T 794.4 1053 T 863.2§,‡ 927 T 1076.3§,‡ 791 T 1094.3§,‡
IFN-F (pg/mL) 3.65 T 1.8 3.85 T 1.95§,‡ 5.25 T 0.90*,† 4.81 T 1.30*,‡
IL-4 (pg/mL) 0.08 T 0.13 0.08 T 0.11§,‡ 0.16 T 0.09*,† 0.16 T 0.13*,†
TGF-A1 (pg/mL) 53,910 T 7525 51,480 T 6084.9§,‡ 40,853 T 12,772||,‡ 45,942 T 9453||,‡
Values are expressed as mean or median T SD; *P G 0.05; ||P G 0.001; §P 9 0.05.
Bold line separates the ﬁrst and second phases; †P G 0.05 between groups; ‡P 9 0.05 between groups.
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Erythema, manifested as maculopapules (7-10 mm in diam-
eter), occurred in all of the patients in the BCG group, but was
not observed in any of placebo group. Neither group showed
evidence of severe ulceration, drainage, or lymphadenitis.
In the thrice BCG group, the weekly symptom score
(SS) and DS were signiﬁcantly decreased beginning on the
fourth week until the 12th week as their peaks, and then began
to increase on the sixth month until the ninth month, but still
better compared with prevaccination (Fig. 2). On the contrary,
in the single BCG group, SS and DS were slightly increased
from the fourth week until the 12th week, and then began to
decrease on the sixth month (P G 0.05), decreased more on the
ninth month, but still better than prevaccination.
In the thrice BCG group, PEFR was signiﬁcantly
increased from the fourth week until the 12th week (P G
0.05), then was slightly decreased from the sixth to the ninth
month, but still better than prevaccination. The FEV1 and
MMEV were all signiﬁcantly increased until the 12th week
prevaccination. On the contrary, in the single BCG group,
PEFR was slightly decreased on the fourth week, then was
more signiﬁcantly decreased on the eighth week and the 12th
week (P G 0.05), but increased again even better than
prevaccination on the sixth month, and then decreased again
on the ninth month, which was worse than prevaccination;
FEV1 and MMEV were all signiﬁcantly decreased on the 12th
week (Fig. 3).
In the thrice BCG group, the EBC was slightly
decreased from baseline to 12 weeks, then further decreased
on the sixth month, which became statistically signiﬁcant on
the ninth month, but in the single BCG group, the decreases in
EBC from the 12th week until the sixth and ninth months were
not signiﬁcant (Fig. 4).
In the thrice and single BCG groups, the mean IgE on
both phases was slightly increased from the 12th week until
the ninth month, except in the single BCG on the ninth month,
which was signiﬁcantly decreased (P G 0.05, Table 2, Fig. 4).
In the thrice and single BCG groups, mean serum IFN-F
was slightly increased on the 12th week but signiﬁcantly
increased (P G 0.05) on the sixth month until the ninth month;
but between the groups, the differences were not signiﬁcant
except on the sixth month (Fig. 5).
Mean serum IL-4 after thrice BCG was signiﬁcantly
increased from the 12th week until the ninth month (P G 0.05),
except that in the single BCG group on the 12th week, it
remained stable and then increased on the sixth and ninth
months. Between the groups on the 12th week, there were no
signiﬁcant differences, but on sixth and ninth months, they
became statistically signiﬁcant (Fig. 5).
Mean serum TGF-A1 after thrice BCG was signiﬁcantly
decreased beginning on the 12th week; on the sixth and ninth
months, they were further very signiﬁcantly decreased (P G
0.001), with its peak on the sixth month. Those patterns were
the same as single BCG, but on the 12th week, it was only
slightly decreased; between the groups, there were no
signiﬁcant differences until the ninth month (Fig. 3).
Besides the scars on the deltoid in the thrice and single
BCG groups, which were 7 to 10 mm in diameter, there were
no other side effects including autoimmune responses or
visiting the emergency department in both groups and in both
phases on 9 months’ follow-up.
Mean serum TGF-A1 in mild and moderate persistent
asthma was not signiﬁcantly different. The serum IFN-F
correlated negatively with serum TGF-A1 on single BCG
vaccination on the sixth month (r = j0.63, P = 0.001).
DISCUSSION
Sex ratio between male and female in the BCG group
was 1:1, and in placebo, 2:3. Mean age was 34.8 years for
both groups; body mass index was normal in both groups.
These were similar to reports by Shirtcliffe et al17 in 2001,
where their mean age was 33 years. But Choi and Koh20
reported a male-female ratio of 4:5 in the BCG group and 1:1
in the placebo group, with a mean age of 47.8 years, subjects
were older than those of this study. Body mass index was
normal between groups, so there was no negative inﬂuence on
immune responses, which was similar to the study by Choi and
Koh,4,20 Aaby et al,16 Shirtcliffe et al,17 and Marks et al.19 The
allergens on both groups were the same, of which house dust
mites were the most prevalent in this study. The duration of
asthma in this study was mostly 5 to 10 years, and the clinical
diagnosis was mostly moderate persistent asthma (70%) on
both groups. In other studies, it was more than 10 years with
severe persistent asthma (65%Y75%), whereas mild persistent
asthma was not included in their studies.19Y22
Choi and Koh4 reported that weekly SS was signiﬁcantly
decreased only on week 7 in the single BCG group, and there
was no difference compared with placebo overall. On the other
FIGURE 5. The IFN-F and IL-4 levels on
BCG vaccination.
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hand, DS was signiﬁcantly decreased in the BCG group and in
the placebo group. In this study, where the budesonide inhaler
was discontinued on both groups, the DS on the placebo group
was increased, higher than baseline but not signiﬁcantly (P 9
0.05). So SS and DS were signiﬁcantly decreased in the thrice
BCG group starting on week 10 until week 12 (P G 0.05) (Fig.
2). The inﬂuence of discontinuing corticosteroid inhalation in
both groups on the eighth week, when the third vaccination
was already done, could not be excluded in the placebo group.
Spirometry was signiﬁcantly increased in the thrice BCG
group (P G 0.05) in this study, this showed a better result than
that of Choi and Koh4 with single BCG.
In the thrice BCG group, the IgE between prevaccina-
tion and postvaccination slightly increased (P G 0.05); and
between postvaccination in both groups was not signiﬁcantly
different, it means that BCG vaccinations could not suppress
the IgE synthesis directly. This was similar to the study of
Lichtenstein et al (cited in Rale and Patterson25) on IgE in
pollen immunotherapy, which increased for several months
and remained high until 1 to 2 years.
Choi and Koh20 gave revaccination to the BCG group
and for the ﬁrst time in the placebo group; examination of
serum IFN-F and IL-4 was done before and after 12 weeks
from vaccination. In our study, after thrice BCG vaccination,
there was slightly increased serum IFN-F after 12 weeks (P 9
0.05) and then was signiﬁcantly increased on the sixth and
ninth months (P G 0.05) (Fig. 5); the increase in serum IFN-F
at 12 weeks in the thrice BCG group was not signiﬁcantly
different from prevaccination in the ﬁrst phase. Perhaps the 4
weeks’ time after the last vaccination was not yet enough to
ﬁnd a signiﬁcant result compared with the evaluation of Choi
and Koh20 after 16 weeks and may be because their dosage
was higher. The signiﬁcant increase in serum IFN-F after
thrice and single BCG vaccination on the sixth and ninth
months reﬂected the immune responses mediated by Th1 cells.
Serum TGF-A1 was signiﬁcantly decreased (P G 0.001) via
immune response stimulation of Th1 cells after thrice and
single BCG vaccination, which increased the IFN-F. The
decrease of EBC in the thrice BCG group on the 12th week
until the sixth month of this study had not occurred
signiﬁcantly, perhaps because of overstimulation by the
antigen of thrice BCG. This was similar to the mean IgE,
which was still increasing until the ninth month, although in
the single BCG group on the ninth month, it began to decrease.
On the contrary, during the ﬁrst phase in placebo group, the
EBC was signiﬁcantly decreased, perhaps inﬂuenced by
corticosteroid inhalation without any antigen stimulation;
and on the sixth and ninth months after single BCG vacci-
nation, the EBC was increased again. These features were si-
milar to the mean IgE under pollen immunotherapy reported
by Lichtenstein et al (cited by Rale and Patterson25). The mean
levels of serum TGF-A1 were also not signiﬁcantly different
between mild and moderate persistent asthma, it means that
the increase in TGF-A1 expression has already occurred and
began in mild persistent asthma. Serum TGF-A1 has a ten-
dency to stimulate the expression and accumulation of ﬁbro-
blast cells, deposition of extracellular matrix and collagen on
peribronchial tissues, and the proliferation and hypertrophy of
bronchial smooth muscle, and all of these will stimulate
hyperreactivity and bronchial obstruction.23 From the results
of the mean PEFR and serum TGF-A1 on the sixth month, we
concluded that the peak of improvement of asthma had
occurred on the sixth month postvaccination, and after that,
the efﬁcacy of BCG vaccination started to decrease in both
groups. Choi and Koh20 reported that the efﬁcacy on PEFR of
BCG revaccination after 1 year was better than single
vaccination. From our study, we found that BCG has the
ability to modulate the asthma immune responses, especially
on increasing IFN-F and inhibiting the expression of EBC, and
serum TGF-A1. The studies of Choi and Koh,4,20 Erb et al,10
Strannegard et al,15 and Hoft et al26 showed the modulating
ability of BCG vaccination to inﬂuence the immune responses
and change the balance of Th1 and Th2. In another study,
Hopfenspirger and Agrawal18 reported on the effect of BCG
vaccination on asthma, they did not reveal differences in mean
IgE between treated and control groups. Hoft et al,26 in their
study on the effect of single BCG on a normal person, reported
the signiﬁcant increase in serum IFN-F and the signiﬁcant
decrease in serum IL-4, but they did not ﬁnd any differences in
IgE between the BCG and placebo groups. They proposed that
BCG vaccination inﬂuences only the immune response that is
mediated by Th1 cells, and not by Th2 cells. Cohn et al27 and
Smart et al28 reported the same thing. This is similar to our
ﬁnding that BCG vaccinations can improve clinical symptoms
and lung function, and signiﬁcantly increase serum IFN-F
levels, although the mean IgE and serum IL-4 also increased
until 6 months. In our study, BCG vaccinations were able to
increase serum IFN-F and suppress serum TGF-A1 and EBC.
This was similar to the reports of Choi and Koh4,20 in Korea,
Strannegard et al15 in Puerto Rico, Aaby et al16 in Guinea-
Bissau, Shirtcliffe et al17 in New Zealand, Marks et al19 in
Australia, and Zuany-Amorin et al29 in Brazil. They were all
successful in showing immune response modulation to
balance the Th1/Th2 in asthmatic patients with BCG vaccine
or Mycobacterium vaccae. Most of their study subjects
(65%j85%) have never had BCG vaccination in childhood.
Moehrenschlager et al30 from the MIRIAM study in Germany
also found no hint that BCG vaccination or whole-cell
pertussis vaccination may lead to higher prevalences of
asthma, allergic rhinitis, eczema, or allergic sensitization at
preschool age. Recently, Martignon et al31 reported a signiﬁ-
cantly reduced risk of having atopic diseases in adolescents
being vaccinated (BCG, diphtheria-tetanus-poliomyelitis,
pertussis) in contrast to nonvaccinated controls, and this effect
was strongest for atopic eczema and stronger in boys than in
girls. On the contrary, the study conducted in regions where
BCG vaccination was not given routinely in childhood, as the
study of Alm et al21 in Sweden and Anderson et al22 in
Belgium, could not show the effectivity of BCG on sup-
pressing Th2 cytokines. The increase in serum IFN-F cor-
related negatively to serum TGF-A1. The TGF-A1 is a major
cytokine of T regulator cells, in particular, it is a potent
regulator of ﬁbroblast and myoﬁbroblast function and controls
the production of several extracellular matrix protein, includ-
ing collagens, proteoglycans, and tenascin. Other cell types
involved in allergic inﬂammation as potential sources of TGF-
A1 include eosinophils, macrophages, mast cells, neutrophils,
endothelial cells, and smooth muscle cells and ﬁbroblasts
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themselves. The thickening of subepithelial lamina reticularis
in bronchial asthma has been related to an increase of
ﬁbroblasts in correlation with TGF-A1 expression. Therapeu-
tic treatment of mice with antiYTGF-A1 antibody signiﬁcantly
reduced peribronchial extracellular matrix deposition, airway
smooth muscle cell proliferation, and mucus production in the
lung (Duvemelle et al, Hashino et al, and Mc Milan et al, as
cited by Akdis et al32). So the decrease of serum TGF-A1 in
this study might contribute to the improvement of clinical
signs and symptoms, and lung function, and the decrease in
eosinophils. The improvement of clinical signs and symptoms
including PEFR could be taken as the best parameter to
monitor the efﬁcacy of BCG vaccination. As a conclusion, we
could see that thrice BCG vaccination is better than a single
one based on lung function from the fourth week until the 12th
week, although on the sixth and ninth months, the differences
were not signiﬁcant. Furthermore, on thrice BCG, serum
IFN-F was signiﬁcantly higher on the sixth month than on
single BCG. Then, on the ninth month, the PEFR and serum
TGF-A1 began to worsen again, although it was still better
than at prevaccination. Maybe after the ninth month for
thrice BCG, one could suggest a ﬁrst booster vaccination.
CONCLUSIONS
The efﬁcacy of thrice BCG vaccination on asthma was
demonstrated by the improvements of SS, DS, FEV1, PEFR,
EBC, IFN-F, and TGF-A1 until 9 months after the last
vaccination, without any side effects.
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